Use of Eltrombopag in Improving Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplantation

Overview

Journal Case Rep Oncol

Publisher Karger

Specialty Oncology

Date 2018 Apr 24

PMID 29681820

Citations 12

Authors

Samip Master

Ashish Dwary

Richard Mansour

Glenn M Mills

Nebu Koshy

Affiliations

Soon will be listed here.

Abstract

Eltrombopag is a thrombopoietin agonist and has been used in aplastic anemia and post-transplantation thrombocytopenia. The c-MPL receptor is present on hematopoietic stem cells. There are no reports of eltrombopag utilization for improving poor graft function in the post-transplant setting. Here were report a case of a young female with post-transplant poor graft function as evident from the low absolute neutrophil count, anemia, and thrombocytopenia on day 60. Eltrombopag was started on day 72 and resulted in improvement in all 3 cell lines. The counts continued to be stable even after eltrombopag was discontinued. The patient tolerated the drug without significant side effects for 1 year.

Citing Articles

Thrombopoietin Receptor Agonists in Post-Hematopoietic Cell Transplantation Complicated by Prolonged Thrombocytopenia: A Comprehensive Review.

Elsayed A, Elsayed B, Elmarasi M, Elsabagh A, Elsayed E, Elmakaty I Immunotargets Ther. 2024; 13:461-486.

PMID: 39290805 PMC: 11407319. DOI: 10.2147/ITT.S463384.

Eltrombopag can promote platelet implantation after allogeneic hematopoietic stem cell transplantation as safely and similarly to thrombopoietin.

Li Y, Kong F, Bai G, Jiang Y, Zhang W, Sun X Front Immunol. 2024; 15:1340908.

PMID: 38650933 PMC: 11033304. DOI: 10.3389/fimmu.2024.1340908.

Eltrombopag for the Treatment of Allogeneic Hematopoietic Stem Cell Transplantation-Related Poor Graft Function.

Arslan Davulcu E, Soyer N, Vural F Cureus. 2023; 15(9):e44555.

PMID: 37790070 PMC: 10544786. DOI: 10.7759/cureus.44555.

Eltrombopag for the Treatment of Poor Graft Function Following Haematopoietic Cell Transplantation: Real-Life Data.

Kircali E, Seval G, Ozturk C, Yilmaz H, Koyun D, Bozdag S Balkan Med J. 2022; 40(1):51-56.

PMID: 36571427 PMC: 9874246. DOI: 10.4274/balkanmedj.galenos.2022.2022-2-48.

Eltrombopag in the treatment of patients with persistent thrombocytopenia after haploidentical peripheral blood stem cell transplantation: a single-center experience.

Yan F, Lu N, Gu Z, Huang W, Wang S, Gao X Ann Hematol. 2021; 101(2):397-408.

PMID: 34735613 DOI: 10.1007/s00277-021-04706-6.

References

Kuter D . Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. Annu Rev Med. 2009; 60:193-206. DOI: 10.1146/annurev.med.60.042307.181154. View

Alexander W, Roberts A, Nicola N, Li R, Metcalf D . Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl. Blood. 1996; 87(6):2162-70. View

Kimura S, Roberts A, Metcalf D, Alexander W . Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin. Proc Natl Acad Sci U S A. 1998; 95(3):1195-200. PMC: 18717. DOI: 10.1073/pnas.95.3.1195. View

Kaushansky K, Lin N, Grossmann A, Humes J, Sprugel K, Broudy V . Thrombopoietin expands erythroid, granulocyte-macrophage, and megakaryocytic progenitor cells in normal and myelosuppressed mice. Exp Hematol. 1996; 24(2):265-9. View

Zeigler F, De Sauvage F, Widmer H, Keller G, Donahue C, Schreiber R . In vitro megakaryocytopoietic and thrombopoietic activity of c-mpl ligand (TPO) on purified murine hematopoietic stem cells. Blood. 1994; 84(12):4045-52. View

Poon L, Di Stasi A, Popat U, Champlin R, Ciurea S . Romiplostim for delayed platelet recovery and secondary thrombocytopenia following allogeneic stem cell transplantation. Am J Blood Res. 2013; 3(3):260-4. PMC: 3755526. View

Erickson-Miller C, Delorme E, Tian S, Hopson C, Landis A, Valoret E . Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells. 2008; 27(2):424-30. PMC: 2729672. DOI: 10.1634/stemcells.2008-0366. View

Qian H, Buza-Vidas N, Hyland C, Jensen C, Antonchuk J, Mansson R . Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells. Cell Stem Cell. 2008; 1(6):671-84. DOI: 10.1016/j.stem.2007.10.008. View

Gurion R, Gafter-Gvili A, Paul M, Vidal L, Ben-Bassat I, Yeshurun M . Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis. Haematologica. 2009; 94(5):712-9. PMC: 2675684. DOI: 10.3324/haematol.2008.002170. View

10.

Geddis A . Congenital amegakaryocytic thrombocytopenia. Pediatr Blood Cancer. 2011; 57(2):199-203. DOI: 10.1002/pbc.22927. View

11.

Dyba J, Tinmouth A, Bredeson C, Matthews J, Allan D . Eltrombopag after allogeneic haematopoietic cell transplantation in a case of poor graft function and systematic review of the literature. Transfus Med. 2016; 26(3):202-7. DOI: 10.1111/tme.12300. View

12.

Hartranft M, Clemmons A, DeRemer D, Kota V . Evaluation of romiplostim for the treatment of secondary failure of platelet recovery among allogeneic hematopoietic stem cell transplant patients. J Oncol Pharm Pract. 2015; 23(1):10-17. DOI: 10.1177/1078155215612240. View

13.

Olnes M, Scheinberg P, Calvo K, Desmond R, Tang Y, Dumitriu B . Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012; 367(1):11-9. PMC: 3422737. DOI: 10.1056/NEJMoa1200931. View

14.

Kaushansky K . Historical review: megakaryopoiesis and thrombopoiesis. Blood. 2008; 111(3):981-6. PMC: 2214745. DOI: 10.1182/blood-2007-05-088500. View

15.

Gill H, Leung G, Lopes D, Kwong Y . The thrombopoietin mimetics eltrombopag and romiplostim in the treatment of refractory aplastic anaemia. Br J Haematol. 2016; 176(6):991-994. DOI: 10.1111/bjh.14024. View

16.

Emmons R, Reid D, Cohen R, Meng G, Young N, Dunbar C . Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood. 1996; 87(10):4068-71. View

17.

Sun H, Tsai Y, Nowak I, Liesveld J, Chen Y . Eltrombopag, a thrombopoietin receptor agonist, enhances human umbilical cord blood hematopoietic stem/primitive progenitor cell expansion and promotes multi-lineage hematopoiesis. Stem Cell Res. 2012; 9(2):77-86. PMC: 3412938. DOI: 10.1016/j.scr.2012.05.001. View